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Abstract
Background: HTLV-I infection has been linked to lung pathology and HTLV-II has been associated
with an increased incidence of pneumonia and acute bronchitis. However it is unknown whether
HTLV-I or -II infection alters pulmonary function.
Methods: We performed pulmonary function testing on HTLV-I, HTLV-II and HTLV seronegative
subjects from the HTLV outcomes study (HOST), including vital capacity (VC), forced expiratory
volume in one second (FEV1), and diffusing lung capacity for carbon monoxide (DLCO) corrected
for hemoglobin and lung volume. Multivariable analysis adjusted for differences in age, gender, race/
ethnicity, height and smoking history.
Results: Mean (standard deviation) pulmonary function values among the 257 subjects were as
follows: FVC = 3.74 (0.89) L, FEV1 = 2.93 (0.67) L, DLCOcorr = 23.82 (5.89) ml/min/mmHg, alveolar
ventilation (VA) = 5.25 (1.20) L and DLCOcorr/VA = 4.54 (0.87) ml/min/mmHg/L. There were no
differences in FVC, FEV1 and DLCOcorr/VA by HTLV status. For DLCOcorr, HTLV-I and HTLV-II
subjects had slightly lower values than seronegatives, but neither difference was statistically
significant after adjustment for confounding.
Conclusions: There was no difference in measured pulmonary function and diffusing capacity in
generally healthy HTLV-I and HTLV-II subjects compared to seronegatives. These results suggest
that previously described HTLV-associated abnormalities in bronchoalveolar cells and fluid may not
affect pulmonary function.
Background
Human T-lymphotropic virus type I (HTLV-I) has been
associated with sporadic cases of chronic bronchiolitis
and alveolitis, especially in patients with concurrent HTLV
associated myelopathy (HAM) [1,2]. HTLV type II (HTLV-
II) has been epidemiologically associated with increased
incidences of bronchitis and pneumonia among HTLV-II
infected persons [3,4].
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Biological studies have demonstrated increased levels of
CD3+/CD25+ lymphocytes [5], HTLV-I proviral load and
HTLV-I tax/rex mRNA expression [6,7], HTLV-I specific
IgA [8], soluble interleukin-2 receptors [9], beta-chemok-
ines [7] and soluble intracellular adhesion molecule-1
(ICAM-1) [10], in bronchoalveolar lavage fluid from
HTLV-I infected humans. In addition, mice transgenic for
HTLV-I p40 tax had lymphocytic infiltration of peribron-
chial and perivascular lung tissues associated with
intrapulmonary expression of tax mRNA [11]. In general,
patients with HTLV myelopathy or uveitis had more pro-
nounced biological changes, but some of these studies
also found biological changes in the lungs of asympto-
matic HTLV-I carriers.
However, whether HTLV-I or HTLV-II alters pulmonary
function is unknown. Such information is important
because the pathologic spectrum of these chronic human
retroviral infections has not been completely described. In
addition, such information would be useful to physicians
who must counsel or treat persons found to be HTLV-I or
-II seropositive by serologic screening at the time of blood
donation, military service, or as part of clinical care asso-
ciated with injection drug use.
We therefore performed standardized pulmonary func-
tion testing (PFT) on HTLV-I and HTLV-II infected per-
sons participating in the HTLV Outcomes Study (HOST),
a prospective multicenter cohort study of the health out-
comes of HTLV infection that was initiated as part of the
National Heart Lung and Blood Institute Retrovirus Epi-
demiology Donor Study.
Methods
Study design and patient population
The enrollment and follow-up procedures of the HOST
have been described in detail elsewhere [4]. In brief, per-
sons found to be seropositive for HTLV-I and HTLV-II at
the time of routine or autologous blood donation in
1990–1992 at five United States blood centers were eligi-
ble for enrollment. HTLV-I and HTLV-II infection status
was confirmed with type-specific serology and/or
polymerase chain reaction testing. Subjects have been fol-
lowed approximately every two years with health history
questionnaires, physical examinations, and blood testing.
At the third biennial visit in 1995–1997, we performed
PFT on a randomly selected subset of HTLV-I and -II pos-
itive subjects at four of the five HOST centers (American
Red Cross Blood Services Southeastern Michigan (Detroit,
MI), American Red Cross Blood Services Southern Califor-
nia (Los Angeles, CA), Blood Centers of the Pacific (San
Francisco, CA), and the Oklahoma Blood Institute (Okla-
homa City, OK)). We also selected seronegative subjects at
the same four centers by strata based upon the age, sex and
racial distribution of the HTLV positive subjects, and
asked them to undergo PFT.
PFT Procedures
In performing the PFTs, we followed standards published
by the American Thoracic Society [12]. Spirometers were
calibrated according to these standards, and subjects per-
formed three forced expirations. We measured forced vital
capacity (FVC) in liters, forced expiratory volume at one
second (FEV1), diffusing lung capacity corrected for
hemoglobin (DLCOcorr) and diffusing lung capacity cor-
rected for hemoglobin and alveolar ventilation (DLCO-
corr/VA). Each subject's best effort, as judged by the highest
sum of vital capacity and FEV1 from among three expira-
tory efforts, was used in the analysis.
Statistical analysis
For each of the pulmonary function measures, means and
95 percent confidence intervals were calculated. The mean
of each parameter was compared between the HTLV-I,
HTLV-II and seronegative groups using ANOVA tests
(PROC GLM). Outcome variables, FVC, FEV1, DLCOcorr
and DLCOcorr/VA were all treated as continuous variables
in the model. Multivariable analysis was performed using
linear regression, adjusting for age (quartiles: ≤ 40, 41–47,
47–53 and 54+), gender (male or female), race/ethnicity
(White, Black, Hispanic, Asian/other), smoking history
(nonsmokers, ex-smokers, and current smokers) and
weight (study population quartiles, ≤ 66 kg, 67–78 kg,
79–88.5 kg and ≥ 88.5 kg). The model evaluated differ-
ences in pulmonary function parameters and their statis-
tical significance when all important confounders, such as
smoking, and characteristics of the study subjects were
taken into consideration. Due to the limited number of
subjects, we were unable to stratify the analysis by center.
Nonetheless, power calculations revealed that the study
was able to detect a 10 percent difference compared to
seronegatives in the parameters measured with power (1
– beta) of 0.65 to 0.85 for HTLV-I, and 0.82 to 0.96 for
HTLV-II. All analyses were done using SAS (SAS version
6.12, Cary, NC).
For each of the pulmonary function measures, means and
95 percent confidence intervals were calculated. The mean
of each parameter was compared between the HTLV-I,
HTLV-II and seronegative groups using ANOVA tests. Mul-
tivariable analysis, adjusted for age, gender, race/ethnic-
ity, smoking history and weight, was performed using
linear regression. Due to the limited number of subjects,
we were unable to stratify the analysis by center. Power
calculations revealed that, relative to the seronegatives,
the study was able to detect a 10 percent decrease in the
parameters measured with power (1 – beta) of 0.65 to
0.85 for HTLV-I and 0.82 to 0.96 for HTLV-II. All analyses
were done using SAS (SAS version 6.12, Cary, NC). TheBMC Pulmonary Medicine 2003, 3 http://www.biomedcentral.com/1471-2466/3/1
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Committee on Human Research of the University of Cali-
fornia San Francisco, San Francisco, CA, USA, has
approved the study.
Results
Among the 258 subjects enrolled in the study, one subject
had only one instead of three expiratory efforts recorded.
This subject was eliminated from further analysis, leaving
a study population of 257; none had adult T-cell leukemia
or HTLV associated myelopathy. The HTLV-I and HTLV-II
subjects were comparable to seronegative subjects with
regard to age, gender and race/ethnicity, except that HTLV-
I subjects were somewhat older, and more likely to be of
black race/ethnicity and to be former smokers (Table 1).
Although the three groups were of similar height, HTLV-I
infected subjects had a non-significant trend toward lower
body weight. Thirty-one percent of the HTLV-II subjects
were current smokers, compared to only 11 percent of the
HTLV-I and seronegative groups. Dating from study
enrollment in 1990–92, incident cases of medically-diag-
nosed pneumonia or acute bronchitis were reported by 22
percent of HTLV-I, 33 percent of HTLV-II, and 21 percent
of seronegative subjects in the current analysis. Data on
log10 proviral load were available from 38 of 46 HTLV-I
subjects (mean = -2.97, standard error 0.24 copies per
PBMC) and from 67 of 84 HTLV-II subjects (mean = -3.46,
standard error 0.21 copies per PBMC).
Mean (standard deviation) pulmonary function values
among all 257 subjects were as follows: FVC = 3.74 (0.89)
L, FEV1 = 2.93 (0.67) L, DLCOcorr = 23.82 (5.89) ml/min/
mmHg, alveolar ventilation (VA) = 5.25 (1.20) L and
DLCOcorr/VA = 4.54 (0.87) ml/min/mmHg/L. These data
were comparable to mean values for men and women
combined reported by the First National Health and
Nutrition Examination (NHANES I) of FVC = 3.82, FEV1 =
2.94 and DLCOcorr = 26.605 [13]. In our study, FVC and
FEV1 were also corrected for height squared (in meters),
yielding values of 1.34 (0.24) L/m2 and 1.05 (0.20) L/m2,
respectively. There was also no significant difference in
small airway flow (FEF25–75) between HTLV infected and
seronegatives (p = 0.47, data not shown).
Table 1: Demographic characteristics, smoking history, respiratory disease history, height and weight of subjects undergoing PFT, 
HTLV cohort study.
Variable HTLV-I n = 46 n(%) HTLV-II n = 84 n(%) HTLV Seronegative n = 
127 n(%)
Age 21–30 1 (2) 0 7 (6)
31–40 7 (15) 17 (20) 28 (22)
41–50 18 (39) 42 (50) 49 (39)
51–60 8 (17) 15 (18) 24 (19)
61 plus 12 (26) 10 (12) 19 (15)
Sex Male 12 (26) 26 (31) 35 (28)
Female 34 (74) 58 (69) 92 (72)
Race/Ethnicity Asian/Other 5 (11) 2 (2) 12 (10)
Black 20 (44) 17 (20) 24 (19)
Hispanic 4 (9) 28 (33) 34 (26)
White 17 (37) 37 (44) 57 (45)
Cigarette Smoking Current Smoker 5 (11) 26 (31) 14 (11)
Ex-Smoker 19 (41) 30 (36) 32 (25)
Never Smoked 22 (48) 28 (33) 81 (64)
Pneumonia and/or Bronchitis 
Diagnosed during study
Yes 10 (22) 28 (33) 26 (21)
No 36 (78) 56 (67) 101 (79)
mean (SD) mean (SD) mean (SD)
Height (Meters) Males 1.74 (0.07) 1.76 (0.07) 1.77 (0.08)
Females 1.62 (0.07) 1.63 (0.08) 1.63 (0.07)
Weight Males 82.0 (11.7) 85.2 (14.4) 89.4 (10.5)
Females 72.9 (14.5) 77.4 (20.2) 76.2 (18.5)BMC Pulmonary Medicine 2003, 3 http://www.biomedcentral.com/1471-2466/3/1
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Figures 1 through 4 show the raw pulmonary function val-
ues, stratified by HTLV status. The HTLV-I group had
slightly lower mean FVC, FEV1 and DLCOcorr than did the
seronegative group, but no such difference was apparent
for the HTLV-II group.
The results of the multivariable linear regression analysis
are presented in Table 2. For both FVC and FEV1 adjusted
for height squared, mean values were only minimally
smaller for the HTLV-I group, and no different at all for
the HTLV-II group, both compared to HTLV seronegatives.
For DLCOcorr, the HTLV-I group had mean values that
were about ten percent lower, and the HTLV-II group
about five percent lower, compared to seronegatives.
However these differences narrowed after adjustment for
potential confounding variables and neither was statisti-
cally significant, although there was a trend toward lower
adjusted DLCOcorr for the HTLV-I group. DLCO cor-
rected for alveolar ventilation (DLCOcorr/VA) showed no
differences between both HTLV groups and seronegatives
in either the unadjusted or the multivariable analysis.
Finally, there was no association between DLCO and the
level of HTLV-I or HTLV-II proviral load among the HTLV
seropositives (data not shown).
Discussion
This study did not reveal significant differences between
HTLV-I or -II infected and uninfected persons in pulmo-
Scatter plot showing values of forced vital capacity (FVC) for each subject, with bars indicating mean, and mean plus and minus  standard deviation, by HTLV status Figure 1
Scatter plot showing values of forced vital capacity (FVC) for each subject, with bars indicating mean, and mean plus and minus 
standard deviation, by HTLV status.BMC Pulmonary Medicine 2003, 3 http://www.biomedcentral.com/1471-2466/3/1
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nary function or diffusing capacity, after adjustment for
confounding variables. This normal pulmonary function
data are in contrast to previous reports of bronchio-alveo-
litis and differences in biological measurements in bron-
cho-alveolar lavage fluid among persons with HTLV-I
infection [1,7].
Most previous reports of HTLV-I bronchio-alveolitis
reported more frequent and severe pathological and bio-
logical abnormalities of bronchoalveolar lavage fluid in
patients with HTLV myelopathy or uveitis compared to
HTLV-I carriers without apparent disease [6,8,14]. Since
our patients were without overt inflammatory disease, we
cannot comment on potential pulmonary function
abnormalities in patients with clinical inflammation.
Likewise a rare case of bronchio-alveolitis among our
study group could have had pulmonary function abnor-
malities that were masked by our comparison of mean
values among the HTLV-I, HTLV-II and seronegative
groups. Finally, our subjects could have had clinical or
subclinical pulmonary inflammation due to HTLV-I or
HTLV-II infection, but this inflammation was not of suffi-
cient severity or duration to manifest measurable decre-
ments in overt pulmonary function.
Data from the cohort study from which these subjects
were drawn has revealed an increased incidence of pneu-
monia and acute bronchitis among HTLV-II, and to a
Scatter plot showing values of forced expiratory volume in one second (FEV1) for each subject, with bars indicating mean, and  mean plus and minus standard deviation, by HTLV status Figure 2
Scatter plot showing values of forced expiratory volume in one second (FEV1) for each subject, with bars indicating mean, and 
mean plus and minus standard deviation, by HTLV status.BMC Pulmonary Medicine 2003, 3 http://www.biomedcentral.com/1471-2466/3/1
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lesser degree HTLV-I, infected humans [3,4]. Those results
were based upon analyses of reported physician diagnoses
of these illnesses, and were adjusted statistically to
account for differences in socioeconomic status, cigarette
smoking and alcohol intake between HTLV infected and
uninfected subjects. Although we initially attributed these
illnesses to an increased susceptibility to bacterial infec-
tion, we now propose the hypothesis that these diagnoses
may have been due to immunological mechanisms as in
cases of HTLV-I bronchio-alveolitis. The negative results
of current study, although reassuring to persons with
HTLV-I or HTLV-II infection, cannot exclude either of
these hypotheses.
Strengths of the current study include its setting in a well
characterized cohort study of humans with laboratory
confirmed HTLV-I and HTLV-II infection, and the inclu-
sion of an appropriate control group. Due to information
gathered in the cohort study, we were also able to control
for other potential confounding variables such as cigarette
smoking and alcohol intake. Weaknesses include moder-
ate size of the study, which made us unable to detect PFT
differences that were less than about ten percent. PFT's
were done at four different sites, which could have
resulted in increased variability of the results. The PFTs
that we used may be insensitive to minor degrees of pul-
monary damage, and with this cross-sectional data we
may have missed a progressive loss of pulmonary func-
tion over time in the HTLV groups.
Scatter plot showing values of diffusing capacity of carbon monoxide corrected for hemoglobin (DLCOcorr) for each subject,  with bars indicating mean, and mean plus and minus standard deviation, by HTLV status Figure 3
Scatter plot showing values of diffusing capacity of carbon monoxide corrected for hemoglobin (DLCOcorr) for each subject, 
with bars indicating mean, and mean plus and minus standard deviation, by HTLV status.BMC Pulmonary Medicine 2003, 3 http://www.biomedcentral.com/1471-2466/3/1
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Scatter plot showing values of diffusing capacity of carbon monoxide corrected for hemoglobin and alveolar ventilation  (DLCOcorr/VA) for each subject, with bars indicating mean, and mean plus and minus standard deviation, by HTLV status Figure 4
Scatter plot showing values of diffusing capacity of carbon monoxide corrected for hemoglobin and alveolar ventilation 
(DLCOcorr/VA) for each subject, with bars indicating mean, and mean plus and minus standard deviation, by HTLV status.
Table 2: Unadjusted and adjusted (for age, sex, race, smoking history and body weight) comparison of pulmonary function values 
between the HTLV-I or HTLV-II groups, versus the HTLV seronegatives.
Seronegative mean HTLV-I vs. Seronegatives HTLV-II vs. Seronegatives
Variable Unadj Diff in Means Adjusted Diff (95%CI) Unadj Diff in Means Adjusted Diff (95%CI)
FVC/height2 (liters/m2) 1.35 -0.09 -0.02 (-0.09, 0.05) 0.02 0.01 (-0.04, 0.07)
FEV1/height2 (liters/m2) 1.06 -0.05 -0.01 (-0.07, 0.05) 0.00 0.00 (-0.04, 0.05)
DLCOcorr (ml/minute/
mmHG)
24.58 -2.31 -1.23 (-3.20, 0.74) -1.31 -0.34 (-1.77, 1.09)
DLCOcorr/VA (ml/
minute/mmHg)
4.6 -0.02 0.05 (-0.28, 0.38) -0.18 0.03 (-0.21, 0.27)Publish with BioMed Central    and   every 
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Conclusions
In conclusion, this moderate size study did not reveal any
statistically significant differences in pulmonary function
between generally healthy HTLV-I or -II infected persons
and comparable HTLV seronegatives. However it could
not rule out subtle differences in lung inflammation that
might lead to functional impairment over a longer follow-
up period. Further studies of the immunologic character-
istics of bronchoalveolar lavage cells from HTLV-I or -II
infected humans are needed, especially in persons with a
history of recurrent pneumonia or acute bronchitis but
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